Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00332020




Registration number
NCT00332020
Ethics application status
Date submitted
30/05/2006
Date registered
31/05/2006
Date last updated
27/01/2015

Titles & IDs
Public title
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Scientific title
RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Hip Replacement.
Secondary ID [1] 0 0
2005-004691-20
Secondary ID [2] 0 0
11357
Universal Trial Number (UTN)
Trial acronym
RECORD 2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prevention 0 0
Venous Thromboembolism 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Blood 0 0 0 0
Clotting disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rivaroxaban (BAY59-7939)
Treatment: Drugs - Enoxaparin

Experimental: Arm 1 -

Active comparator: Arm 2 -


Treatment: Drugs: Rivaroxaban (BAY59-7939)
10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days

Treatment: Drugs: Enoxaparin
40 mg enoxaparin syringe administered for 12 +/- 2 days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes
Timepoint [1] 0 0
Treatment period: up to day 35+/-6
Secondary outcome [1] 0 0
Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE)
Timepoint [1] 0 0
Treatment period: up to day 35+/-6
Secondary outcome [2] 0 0
Incidence of symptomatic VTE (DVT, PE)
Timepoint [2] 0 0
Treatment period: up to day 35+/-6
Secondary outcome [3] 0 0
Incidence of DVT (total, proximal, distal)
Timepoint [3] 0 0
Treatment period: up to day 35+/-6
Secondary outcome [4] 0 0
Incidence of symptomatic VTE during follow-up
Timepoint [4] 0 0
Follow-up period: following 35+/-6 days
Secondary outcome [5] 0 0
The composite endpoint comprising major VTE and treatment-emergent major bleeding
Timepoint [5] 0 0
For major VTE, treatment period: up to Day 35+/-6 ; for major bleeding, from first dose of double-blind study medication to up to two days after last dose of double-blind study medication
Secondary outcome [6] 0 0
Incidence of the composite endpoint that results from the primary endpoint by substituting VTE related death for all death
Timepoint [6] 0 0
Treatment period: up to day 35+/-6
Secondary outcome [7] 0 0
Incidence of the composite endpoint that results from major VTE by substituting all cause mortality for VTE-related death
Timepoint [7] 0 0
Treatment period: up to day 35+/-6
Secondary outcome [8] 0 0
Treatment-emergent major bleedings
Timepoint [8] 0 0
From first dose of double-blind study medication to up to two days after last dose of double-blind study medication

Eligibility
Key inclusion criteria
* Male and female patients aged 18 years or above
* Patients scheduled for elective total hip replacement
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Planned, staged total bilateral hip replacement
* Active bleeding or high risk of bleeding contraindicating treatment with low molecular weight heparin
* Contraindication listed in the labeling or conditions precluding patient treatment with enoxaparin
* Conditions prohibiting bilateral venography (e.g. amputation of one leg, allergy to contrast media)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2007
Sample size
Target
Accrual to date
Final
2457
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC
Recruitment hospital [1] 0 0
- Canberra
Recruitment hospital [2] 0 0
- Lismore
Recruitment hospital [3] 0 0
- Sydney
Recruitment hospital [4] 0 0
- Southport
Recruitment hospital [5] 0 0
- Geelong
Recruitment hospital [6] 0 0
- Melbourne
Recruitment postcode(s) [1] 0 0
2605 - Canberra
Recruitment postcode(s) [2] 0 0
2480 - Lismore
Recruitment postcode(s) [3] 0 0
2065 - Sydney
Recruitment postcode(s) [4] 0 0
4215 - Southport
Recruitment postcode(s) [5] 0 0
3220 - Geelong
Recruitment postcode(s) [6] 0 0
3128 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Oklahoma
Country [5] 0 0
Brazil
State/province [5] 0 0
Minas Gerais
Country [6] 0 0
Brazil
State/province [6] 0 0
Paraná
Country [7] 0 0
Brazil
State/province [7] 0 0
Rio Grande do Sul
Country [8] 0 0
Brazil
State/province [8] 0 0
Sao Paulo
Country [9] 0 0
Brazil
State/province [9] 0 0
SP
Country [10] 0 0
Brazil
State/province [10] 0 0
Rio de Janeiro
Country [11] 0 0
Canada
State/province [11] 0 0
Alberta
Country [12] 0 0
Canada
State/province [12] 0 0
British Columbia
Country [13] 0 0
Canada
State/province [13] 0 0
Manitoba
Country [14] 0 0
Canada
State/province [14] 0 0
New Brunswick
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
China
State/province [16] 0 0
Guangdong
Country [17] 0 0
China
State/province [17] 0 0
Shandong
Country [18] 0 0
China
State/province [18] 0 0
Shanxi
Country [19] 0 0
China
State/province [19] 0 0
Beijing
Country [20] 0 0
China
State/province [20] 0 0
Shanghai
Country [21] 0 0
Colombia
State/province [21] 0 0
Barranquilla
Country [22] 0 0
Colombia
State/province [22] 0 0
Bogotá
Country [23] 0 0
Colombia
State/province [23] 0 0
Cali
Country [24] 0 0
Colombia
State/province [24] 0 0
Medellín
Country [25] 0 0
Denmark
State/province [25] 0 0
Copenhagen
Country [26] 0 0
Denmark
State/province [26] 0 0
Frederiksberg
Country [27] 0 0
Denmark
State/province [27] 0 0
Glostrup
Country [28] 0 0
Denmark
State/province [28] 0 0
Herlev
Country [29] 0 0
Denmark
State/province [29] 0 0
Holbaek
Country [30] 0 0
Denmark
State/province [30] 0 0
Hvidovre
Country [31] 0 0
Denmark
State/province [31] 0 0
Silkeborg
Country [32] 0 0
Denmark
State/province [32] 0 0
Viborg
Country [33] 0 0
Estonia
State/province [33] 0 0
Tallinn
Country [34] 0 0
Estonia
State/province [34] 0 0
Tartu
Country [35] 0 0
India
State/province [35] 0 0
Andhra Pradesh
Country [36] 0 0
India
State/province [36] 0 0
Andra Pradesh
Country [37] 0 0
India
State/province [37] 0 0
Punjab
Country [38] 0 0
India
State/province [38] 0 0
Bangalore
Country [39] 0 0
India
State/province [39] 0 0
Mumbai
Country [40] 0 0
Indonesia
State/province [40] 0 0
West Java
Country [41] 0 0
Indonesia
State/province [41] 0 0
Surabaya
Country [42] 0 0
Italy
State/province [42] 0 0
Genova
Country [43] 0 0
Italy
State/province [43] 0 0
Lecco
Country [44] 0 0
Italy
State/province [44] 0 0
Modena
Country [45] 0 0
Italy
State/province [45] 0 0
Napoli
Country [46] 0 0
Italy
State/province [46] 0 0
Parma
Country [47] 0 0
Italy
State/province [47] 0 0
Siena
Country [48] 0 0
Italy
State/province [48] 0 0
Udine
Country [49] 0 0
Korea, Republic of
State/province [49] 0 0
Daegu
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Kyunggido
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Seoul
Country [52] 0 0
Latvia
State/province [52] 0 0
Liepaja
Country [53] 0 0
Latvia
State/province [53] 0 0
Riga
Country [54] 0 0
Lithuania
State/province [54] 0 0
Kaunas
Country [55] 0 0
Lithuania
State/province [55] 0 0
Klaipeda
Country [56] 0 0
Lithuania
State/province [56] 0 0
Panevezys
Country [57] 0 0
Lithuania
State/province [57] 0 0
Siauliai
Country [58] 0 0
Mexico
State/province [58] 0 0
Chihuahua
Country [59] 0 0
Mexico
State/province [59] 0 0
Jalisco
Country [60] 0 0
New Zealand
State/province [60] 0 0
Auckland
Country [61] 0 0
Norway
State/province [61] 0 0
Kongsvinger
Country [62] 0 0
Norway
State/province [62] 0 0
Namsos
Country [63] 0 0
Norway
State/province [63] 0 0
Oslo
Country [64] 0 0
Norway
State/province [64] 0 0
Tynset
Country [65] 0 0
Peru
State/province [65] 0 0
Callao
Country [66] 0 0
Peru
State/province [66] 0 0
Lima Cercado
Country [67] 0 0
Peru
State/province [67] 0 0
Lima
Country [68] 0 0
Portugal
State/province [68] 0 0
Lisboa
Country [69] 0 0
Portugal
State/province [69] 0 0
Porto
Country [70] 0 0
Portugal
State/province [70] 0 0
Setúbal
Country [71] 0 0
Portugal
State/province [71] 0 0
Torres Vedras
Country [72] 0 0
South Africa
State/province [72] 0 0
Freestate
Country [73] 0 0
South Africa
State/province [73] 0 0
Gauteng
Country [74] 0 0
South Africa
State/province [74] 0 0
Kwa Zulu-Natal
Country [75] 0 0
South Africa
State/province [75] 0 0
Western Cape
Country [76] 0 0
Sweden
State/province [76] 0 0
Falköping
Country [77] 0 0
Sweden
State/province [77] 0 0
Hässleholm
Country [78] 0 0
Sweden
State/province [78] 0 0
Kungälv
Country [79] 0 0
Sweden
State/province [79] 0 0
Lidköping
Country [80] 0 0
Sweden
State/province [80] 0 0
Stockholm
Country [81] 0 0
Sweden
State/province [81] 0 0
Sundsvall
Country [82] 0 0
Sweden
State/province [82] 0 0
Varberg
Country [83] 0 0
Sweden
State/province [83] 0 0
Växjö
Country [84] 0 0
Sweden
State/province [84] 0 0
Örebro
Country [85] 0 0
Taiwan
State/province [85] 0 0
Kaohsiung
Country [86] 0 0
Taiwan
State/province [86] 0 0
Taoyuan
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Derbyshire
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Dumfries and Galloway
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Fife
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Greater London
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Merseyside
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Norfolk
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Northamptonshire
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.
Trial website
https://clinicaltrials.gov/study/NCT00332020
Trial related presentations / publications
Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. doi: 10.1016/S0140-6736(08)60880-6. Epub 2008 Jun 24.
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00332020